https://pharmadog.xyz/news/232743 pharmadog en 2026-08-12T07:00:00.000Z Missed promotion often reflects organizational timing, not personal failure https://pharmadog.xyz/news/232103 pharmadog en 2026-08-12T05:38:00.000Z AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development model https://pharmadog.xyz/news/231119 pharmadog en 2026-08-11T22:30:00.000Z French study finds stopping statins in low-risk adults over 75 does not raise mortality https://pharmadog.xyz/news/231120 pharmadog en 2026-08-11T22:18:55.000Z Medicaid to End Funding for Gender-Affirming Surgeries and Hormone Therapy for Transgender Youth https://pharmadog.xyz/news/230082 pharmadog en 2026-08-11T18:29:51.000Z Researchers suspect Exelixis used a minor tweak to cabozantinib to sidestep patent cliff https://pharmadog.xyz/news/230083 pharmadog en 2026-08-11T18:25:36.000Z AbbVie, Novartis and Bristol Myers Squibb sue Illinois over 340B drug discount law https://pharmadog.xyz/news/229751 pharmadog en 2026-08-11T16:57:34.000Z Health industry pushes back against Trump’s vaccine executive order https://pharmadog.xyz/news/229752 pharmadog en 2026-08-11T16:46:06.000Z Trump’s vaccine executive order likely erodes public trust, says epidemiologist https://pharmadog.xyz/news/229535 pharmadog en 2026-08-11T16:12:00.000Z Former Legend Biotech CEO Ying Huang appointed head of K2 Therapeutics as startup secures $50M seed funding https://pharmadog.xyz/news/229431 pharmadog en 2026-08-11T15:47:19.000Z Health insurers' AI spending meets reality check as UnitedHealth pledges $1.5 billion and CVS outlines its own budget https://pharmadog.xyz/news/229545 pharmadog en 2026-08-11T15:06:00.000Z Henkel recalls Schwarzkopf Professional Osis Grip mousse in U.S. over packaging leak risk https://pharmadog.xyz/news/229215 pharmadog en 2026-08-11T14:44:13.000Z Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million funding https://pharmadog.xyz/news/229142 pharmadog en 2026-08-11T14:28:57.000Z Experts warn splitting MMR vaccine into separate shots could increase missed doses and illness https://pharmadog.xyz/news/134233 pharmadog en 2026-08-11T14:21:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/229143 pharmadog en 2026-08-11T14:19:47.000Z Trump pushes controversial changes to MMR vaccine policy, eclipsing new food additive rule https://pharmadog.xyz/news/228983 pharmadog en 2026-08-11T13:55:51.000Z FDA issues complete response letter rejecting ITM Isotope's radiopharma therapy over manufacturing concerns https://pharmadog.xyz/news/230057 pharmadog en 2026-08-11T13:42:00.000Z Amgen to open new R&D Science and Innovation Center in Hyderabad's Genome Valley by 2027 https://pharmadog.xyz/news/229043 pharmadog en 2026-08-11T13:40:00.000Z Infinimmune secures $75 million Series A to develop longer-lasting eczema antibody therapies https://pharmadog.xyz/news/229003 pharmadog en 2026-08-11T13:27:20.000Z FDA rejects ITM Isotope's radiopharmaceutical therapy over manufacturing problems, halting potential competitor to Novartis https://pharmadog.xyz/news/228767 pharmadog en 2026-08-11T13:15:49.000Z Nurses voice concerns on AI while regulators outline RAPID pathway for breakthrough devices https://pharmadog.xyz/news/228723 pharmadog en 2026-08-11T13:00:25.000Z Hims & Hers says it can quickly launch six wellness peptides if FDA lifts ban https://pharmadog.xyz/news/228747 pharmadog en 2026-08-11T12:59:56.000Z Scholar Rock pulls Indiana fill-finish plant from SMA therapy filing after FDA flags violations https://pharmadog.xyz/news/228724 pharmadog en 2026-08-11T12:54:59.000Z Epicrispr raises $90 million Series C after promising early data on epigenetic FSHD therapy https://pharmadog.xyz/news/228748 pharmadog en 2026-08-11T12:14:53.000Z Insilico Medicine CEO touts billions in pipeline deals at BIO International Convention https://pharmadog.xyz/news/228599 pharmadog en 2026-08-11T12:01:00.000Z Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programs https://pharmadog.xyz/news/228555 pharmadog en 2026-08-11T12:00:44.000Z Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assets https://pharmadog.xyz/news/228619 pharmadog en 2026-08-11T12:00:00.000Z Skylark Bio launches first-in-human gene therapy trial targeting deafness https://pharmadog.xyz/news/228659 pharmadog en 2026-08-11T12:00:00.000Z Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHD https://pharmadog.xyz/news/229045 pharmadog en 2026-08-11T11:43:00.000Z Trump signs executive order to split MMR vaccine and reduce U.S. childhood immunization schedule https://pharmadog.xyz/news/228471 pharmadog en 2026-08-11T11:10:09.000Z AbCellera’s antibody ABCL635 cuts hot flash frequency in early trial, outperforms oral competitors https://pharmadog.xyz/news/228304 pharmadog en 2026-08-11T11:01:03.000Z Silence causes uproar in rare blood cancer space as data sets high bar for competitors https://pharmadog.xyz/news/228231 pharmadog en 2026-08-11T11:00:15.000Z Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapy https://pharmadog.xyz/news/228305 pharmadog en 2026-08-11T11:00:00.000Z Vaderis raises $152M Series B to launch Phase 3 trial of engasertib for hereditary hemorrhagic telangiectasia https://pharmadog.xyz/news/228344 pharmadog en 2026-08-11T11:00:00.000Z Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorder https://pharmadog.xyz/news/229190 pharmadog en 2026-08-11T09:56:00.000Z Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle disease https://pharmadog.xyz/news/229073 pharmadog en 2026-08-11T09:38:00.000Z Zydus Sentynl signs up to $475M deal to license Mereo's phase-3 ready rare lung disease drug alvelestat in U.S. https://pharmadog.xyz/news/227834 pharmadog en 2026-08-11T08:30:00.000Z Medicare’s new $50 GLP‑1 weight‑loss drug program may create barriers for patients, warns experts https://pharmadog.xyz/news/227835 pharmadog en 2026-08-11T08:30:00.000Z Abortion care shifts to remote and private channels as patients seek help outside clinics https://pharmadog.xyz/news/227832 pharmadog en 2026-08-11T08:30:00.000Z MoonLake Immunotherapeutics’ vague data on its autoimmune candidate draws criticism https://pharmadog.xyz/news/227836 pharmadog en 2026-08-11T08:30:00.000Z Nonprofit North Star Review Board offers independent model to fix IRB oversight issues https://pharmadog.xyz/news/227833 pharmadog en 2026-08-11T08:30:00.000Z Nurses push for involvement as AI threatens jobs and patient care https://pharmadog.xyz/news/228916 pharmadog en 2026-08-11T08:18:00.000Z Aura Biosciences cuts 20% of staff and reshuffles C-suite to focus on ocular oncology https://pharmadog.xyz/news/227379 pharmadog en 2026-08-11T07:00:00.000Z Austria launches up to €100 million anchor investment for growth fund, aiming to channel half‑billion euros into biotech https://pharmadog.xyz/news/230500 pharmadog en 2026-08-11T04:00:00.000Z Hamilton Medical issues recall of coaxial breathing circuit sets for C1, T-1 and MR1 ventilators https://pharmadog.xyz/news/228787 pharmadog en 2026-08-11T03:19:00.000Z Abbott partners with Google Health to add AI-driven insights to its Lingo glucose wearable https://pharmadog.xyz/news/232025 pharmadog en 2026-08-11T00:00:00.000Z PIC/S releases revised guide on qualification and validation studies for pharma manufacturing https://pharmadog.xyz/news/232026 pharmadog en 2026-08-11T00:00:00.000Z Drug makers and animal testing groups urge FDA to keep flexible guidance on animal studies for cancer drugs https://pharmadog.xyz/news/232027 pharmadog en 2026-08-11T00:00:00.000Z FDA rejects ITM radiopharma therapy while WHO defends immunization schedules https://pharmadog.xyz/news/225063 pharmadog en 2026-08-10T20:32:45.000Z Trump orders MMR vaccine to be administered as three separate shots, citing autism concerns https://pharmadog.xyz/news/224723 pharmadog en 2026-08-10T19:29:51.000Z Trump administration issues executive order questioning childhood vaccine schedule https://pharmadog.xyz/news/224679 pharmadog en 2026-08-10T19:05:00.000Z FDA rejects ITM's radiopharma drug for neuroendocrine tumors over manufacturing issues https://pharmadog.xyz/news/224454 pharmadog en 2026-08-10T18:20:19.000Z Bristol Myers Squibb announces $2.3 billion manufacturing campus in Houston https://pharmadog.xyz/news/224295 pharmadog en 2026-08-10T17:43:22.000Z Federal judge suspends Pentagon's designation of WuXi AppTec as a Chinese military-linked firm https://pharmadog.xyz/news/224339 pharmadog en 2026-08-10T17:36:47.000Z BMS commits $2.3 billion to build modular manufacturing campus in Houston, creating 2,500 jobs https://pharmadog.xyz/news/224178 pharmadog en 2026-08-10T17:08:01.000Z Scholar Rock removes Indiana manufacturing site from SMA drug application after FDA cites deficiencies https://pharmadog.xyz/news/228422 pharmadog en 2026-08-10T16:31:00.000Z Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup Infinimmune https://pharmadog.xyz/news/224026 pharmadog en 2026-08-10T16:22:59.000Z Sionna’s cystic fibrosis candidate misses primary endpoint in Phase 2 trial, shares plunge https://pharmadog.xyz/news/223803 pharmadog en 2026-08-10T15:39:45.000Z Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to Vertex https://pharmadog.xyz/news/223907 pharmadog en 2026-08-10T15:36:00.000Z Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billion https://pharmadog.xyz/news/223686 pharmadog en 2026-08-10T15:33:49.000Z AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31% https://pharmadog.xyz/news/223687 pharmadog en 2026-08-10T15:33:02.000Z RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 success https://pharmadog.xyz/news/223631 pharmadog en 2026-08-10T15:11:07.000Z FDA rejects ITM-11 radiopharmaceutical over manufacturing flaws, halting rival to Novartis therapy https://pharmadog.xyz/news/223632 pharmadog en 2026-08-10T15:00:00.000Z FDA to require companies to notify agency of new food additives, creating public database https://pharmadog.xyz/news/223633 pharmadog en 2026-08-10T14:52:16.000Z Calls to Ban Prior Authorizations Amid Hospital Job Cuts Highlight Health‑Care Policy Debate https://pharmadog.xyz/news/223611 pharmadog en 2026-08-10T14:50:01.000Z Sionna’s Phase 2a CF trial fails, shares plunge as Vertex’s Trikafta remains standard of care https://pharmadog.xyz/news/223634 pharmadog en 2026-08-10T14:48:07.000Z FDA advisory panel set to review Grail’s multi-cancer Galleri screening test https://pharmadog.xyz/news/223613 pharmadog en 2026-08-10T14:42:33.000Z Jazz Pharma to acquire Actio Biosciences for up to $1.3 billion, adding experimental KCNT1 epilepsy drug https://pharmadog.xyz/news/223474 pharmadog en 2026-08-10T14:37:15.000Z Psychedelic firms Definium and Compass poised for key data releases https://pharmadog.xyz/news/223475 pharmadog en 2026-08-10T14:36:19.000Z AstraZeneca and CSPC launch joint venture to build biologics plant in Shijiazhuang https://pharmadog.xyz/news/223542 pharmadog en 2026-08-10T14:30:00.000Z Aspo Plc reports managers' transactions on August 10, 2026 https://pharmadog.xyz/news/223543 pharmadog en 2026-08-10T14:30:00.000Z Aspo Oyj announces upcoming leadership changes scheduled for August 10, 2026 https://pharmadog.xyz/news/224028 pharmadog en 2026-08-10T14:25:05.000Z Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol gene https://pharmadog.xyz/news/223291 pharmadog en 2026-08-10T13:45:18.000Z Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million upfront, targeting ultra-rare epilepsy https://pharmadog.xyz/news/228206 pharmadog en 2026-08-10T13:45:00.000Z Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular disease https://pharmadog.xyz/news/223355 pharmadog en 2026-08-10T13:24:23.000Z Sanofi faces shortage of two Pompe disease drugs after FDA flags manufacturing issues https://pharmadog.xyz/news/223079 pharmadog en 2026-08-10T12:57:39.000Z Tenax Therapeutics' heart failure drug TNX-103 misses primary endpoint in Phase 3, shares plunge 85% https://pharmadog.xyz/news/222931 pharmadog en 2026-08-10T12:03:17.000Z Sionna's CF add-on pill fails to improve outcomes in Phase 2 trial with Trikafta https://pharmadog.xyz/news/123082 pharmadog en 2026-08-10T11:53:00.000Z Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines https://pharmadog.xyz/news/222803 pharmadog en 2026-08-10T11:38:20.000Z Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumble https://pharmadog.xyz/news/222759 pharmadog en 2026-08-10T11:31:25.000Z Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 success https://pharmadog.xyz/news/222804 pharmadog en 2026-08-10T11:31:00.000Z Silence Therapeutics’ divesiran shows 88% response in Phase 2 polycythemia vera trial, challenging Takeda’s upcoming drug https://pharmadog.xyz/news/222784 pharmadog en 2026-08-10T11:20:01.000Z BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme asset https://pharmadog.xyz/news/223661 pharmadog en 2026-08-10T11:09:00.000Z FDA issues complete response letter rejecting ITM’s neuroendocrine tumor drug over manufacturing concerns https://pharmadog.xyz/news/222651 pharmadog en 2026-08-10T11:00:22.000Z BioNTech veteran secures $25M seed round for virtual cancer surveillance startup https://pharmadog.xyz/news/222547 pharmadog en 2026-08-10T10:42:13.000Z Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecasts https://pharmadog.xyz/news/223425 pharmadog en 2026-08-10T10:09:00.000Z Scholar Rock removes Novo Nordisk's Catalent plant from FDA filing for SMA drug apitegromab https://pharmadog.xyz/news/223662 pharmadog en 2026-08-10T10:00:00.000Z MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritis https://pharmadog.xyz/news/223562 pharmadog en 2026-08-10T09:48:00.000Z Jazz Pharma to acquire Actio Biosciences for $820M, adding KCNT1+ epilepsy drug to its pipeline https://pharmadog.xyz/news/223426 pharmadog en 2026-08-10T09:39:00.000Z Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex